Episode 111: ASCO 2024 - Genitourinary Cancers (Prostate/Penile)

The second of our two GU ASCO 2024 episodes focusses on prostate and penile cancer, two diseases at different ends of the therapeutic spectrum. Prostate cancer is one of the most common cancers in men, with well established, nuanced treatment paradigms and a glut of high-quality evidence. Penile SCC is a very rare cancer that tragically is much more common in low socioeconomic countries. Treatment options are as limited as available evidence, so any new studies of this cancer are very welcome. Are there any more practice changing twists and turns from ASCO 2024? You'll have to listen to find out!

Links to studies discussed in this episode (subscription may be required)

Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153): Link

CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer: Link

A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study: Link

A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. Link